Breaking News Instant updates and real-time market news.

AMRN

Amarin

$14.22

0.33 (2.38%)

, NVO

Novo Nordisk

$51.47

1.12 (2.22%)

10:20
08/13/19
08/13
10:20
08/13/19
10:20

Roth confident Amarin's Vascepa will be 'well-received' by FDA panel

Roth Capital analyst Yasmeen Rahimi noted that the FDA's upcoming Advisory Committee reviewing the sNDA for Amarin's (AMRN) Vascepa will include ten voting and one non-voting committee members, including five endocrinologists, three cardiologists, a biostatistician, a pharmacoepidemiologist, a consumer representative and a non-voting nephrologist. Given that the American Diabetes Association has included Vascepa for CV risk reduction in its recommended treatment guidelines, and the panel has a majority of endocrinologists, she believes that "the committee is primed for a positive reception of Vascepa," Rahimi tells investors. Additionally, the AdCom Chairperson, Dr. Kenneth Burman, previously voted in favor of Novo Nordisk's (NVO) insulin degludec and insulin degludec/aspart when chairing a prior AdCom. Rahimi reads this as a strong sign that he is receptive to new therapies and as a positive for Vascepa's review, she said. The analyst keeps a Buy rating on Amarin shares with a price target of $31.

AMRN

Amarin

$14.22

0.33 (2.38%)

NVO

Novo Nordisk

$51.47

1.12 (2.22%)

  • 15

    Aug

  • 09

    Sep

  • 25

    Sep

  • 28

    Sep

AMRN Amarin
$14.22

0.33 (2.38%)

08/01/19
SBSH
08/01/19
NO CHANGE
Target $23
SBSH
Buy
Amarin shares already pricing in Vascepa label expansion, says Citi
Citi analyst Joel Beatty agrees with Amarin that an FDA panel for the Vascepa label expansion is unlikely given that less than two months remain until the action date of September 28. However, approval of a cardiovascular risk reduction claim for Vascepa is already priced in to the stock, Beatty tells investors in a research note. As such, the analyst does not expect much stock movement around the PDUFA date. Upside would be if a very broad label is granted, such as no triglyceride level cutoff, says Beatty. The analyst believes that for Amarin shares to reach his unchanged price target of $23, Vascepa sales need to reach his 2020 sales projection of $769M, which is a 91% increase above the current annual run rate of $401M. This is realistic, however, given the direct-to-consumer advertising planned to begin in Q2 of 2020, as many primary care physicians "relatively unfamiliar" with Vascepa will begin to be repeatedly asked about it by patients, contends the analyst. He keeps a Buy rating on Amarin. The stock closed Wednesday up 15c to $18.59.
08/09/19
CANT
08/09/19
NO CHANGE
Target $35
CANT
Overweight
Amarin selloff on surprise FDA panel meeting overdone, says Cantor Fitzgerald
Amarin's announcement last night that the FDA plans to hold an advisory committee meeting, tentatively scheduled for November 14, came as a surprise, Cantor Fitzgerald analyst Louise Chen tells investors in a research note titled "No Heartbreak Here, Negative Reaction To AdCom Is Overdone, In Our View." That being said, the stock weakness in reaction to the news is overdone, says Chen. Amarin shares are down 21%, or $3.66, to $14.15 in premarket trading. The potential three-month extension to the FDA action date does not impact Vascepa's potentially multi-billion dollar peak sales opportunity, argues the analyst. Chen keeps an Overweight rating on Amarin with a $35 price target.
08/09/19
HCWC
08/09/19
NO CHANGE
Target $51
HCWC
Buy
Amarin FDA panel driven by agency's conservative approach, says H.C. Wainwright
The FDA's decision to host an Advisory Committee meeting could be driven more by the agency's conservative approach to an expanded cardiovascular event risk reduction label potentially impacting tens of millions of Americans, than any immediate concerns regarding Amarin's REDUCE-IT results themselves, H.C. Wainwright analyst Andrew Fein tells investors in a research note. Management noted the expanded Vascepa label has the potential to be the first indication to impact as many as a third of American adults, and along these lines the FDA holding an AdCom "represents vigilance above all else," contends the analyst. He continues to emphasize that the current stage of commercial development "could potentially represent just the tip of the iceberg for Vascepa." Fein downplays the significance of the AdCom in terms of "materially influencing" the overall approval path for Vascepa's expanded label and reiterates his belief of Vascepa "as a game changing drug." He believes the AdCom timing can be quantifiably valued and is "only worth" approximately a $2-$3 potential hit to his price target of $51. Fein reiterates a Buy rating on Amarin.
08/09/19
JEFF
08/09/19
NO CHANGE
Target $30
JEFF
Buy
Amarin selloff on FDA panel a buying opportunity, says Jefferies
Jefferies analyst Michael Yee views today's selloff in shares of Amarin as a buying opportunity. It is reasonable to have a drug this big discussed in public forum, Yee tells investors in a research note. While the FDA panel brings "some new risk," the corresponding stock selloff more than reflecting this, says Yee. He sees a "buying opportunity since approval is very likely." Yee reiterates a Buy rating on Amarin with a $30 price target.
NVO Novo Nordisk
$51.47

1.12 (2.22%)

06/11/19
LEHM
06/11/19
UPGRADE
LEHM
Equal Weight
Novo Nordisk upgraded to Equal Weight from Underweight at Barclays
Barclays analyst Emmanuel Papadakis upgraded Novo Nordisk (NVO) to Equal Weight from Underweight and raised his price target for the shares to 325 kronor from 275 kronor. The analyst views competitor updates at the American Diabetes Association conference, specifically from Eli Lilly (LLY), as "underwhelming."
06/20/19
DBAB
06/20/19
DOWNGRADE
DBAB
Hold
Novo Nordisk downgraded to Hold from Buy at Deutsche Bank
Deutsche Bank analyst Richard Parkes downgraded Novo Nordisk to Hold from Buy citing valuation.
06/20/19
06/20/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Novo Nordisk (NVO) downgraded to Hold from Buy at Deutsche Bank with analyst Richard Parkes citing valuation. 2. Shopify (SHOP) downgraded to Neutral from Outperformer at CIBC with analyst Todd Coupland stating that while he is encouraged by the company's product announcements, he believes the upside seen in his investment thesis has now been priced into the stock. 3. Enphase Energy (ENPH) downgraded to Neutral from Buy at H.C. Wainwright with analyst Amit Dayal saying at current levels, the shares are more than adequately pricing in another earnings beat for Q2 and potential guidance raise for 2019. 4. Hershey (HSY) downgraded to Underweight from Neutral at Piper Jaffray with analyst Michael Lavery stating the company has a U.S.-centric portfolio with generally stable sales and earnings growth, but the valuation at current share levels "now looks inconsistent with consensus expectations". 5. Carnival (CCL) downgraded to Market Perform from Outperform at William Blair with analyst Sharon Zackfia noting the company lowered expectations for the remainder of the fiscal year, with constant-currency net yields now expected to be flattish to slightly down in Q3 and down in Q4. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/05/19
PART
08/05/19
UPGRADE
PART
Buy
Novo Nordisk upgraded to Buy from Hold at Pareto

TODAY'S FREE FLY STORIES

03:25
08/21/19
08/21
03:25
08/21/19
03:25
General news
FX Action: USD-CAD yesterday matched the two-month high »

FX Action: USD-CAD…

02:55
08/21/19
08/21
02:55
08/21/19
02:55
General news
FX Update: The main currencies have been steady »

FX Update: The main…

02:10
08/21/19
08/21
02:10
08/21/19
02:10
General news
Asian Market Wrap: »

Asian Market Wrap:…

HA

Hawaiian Holdings

$25.44

0.31 (1.23%)

21:12
08/20/19
08/20
21:12
08/20/19
21:12
Downgrade
Hawaiian Holdings rating change at Stifel »

Hawaiian Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 05

    Sep

MHK

Mohawk

$112.98

-1.05 (-0.92%)

21:06
08/20/19
08/20
21:06
08/20/19
21:06
Upgrade
Mohawk rating change at Wells Fargo »

Mohawk upgraded to Market…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNV

Synovus

$35.18

-0.78 (-2.17%)

21:01
08/20/19
08/20
21:01
08/20/19
21:01
Initiation
Synovus initiated at DA Davidson »

Synovus initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 28

    Aug

  • 29

    Aug

  • 23

    Sep

BXS

BancorpSouth

$27.49

-0.415 (-1.49%)

20:59
08/20/19
08/20
20:59
08/20/19
20:59
Initiation
BancorpSouth initiated at DA Davidson »

BancorpSouth initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

UCBI

United Community Banks

$26.63

-0.36 (-1.33%)

20:57
08/20/19
08/20
20:57
08/20/19
20:57
Initiation
United Community Banks initiated at DA Davidson »

United Community Banks…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Sep

  • 17

    Sep

RNST

Renasant

$33.20

-0.375 (-1.12%)

20:57
08/20/19
08/20
20:57
08/20/19
20:57
Initiation
Renasant initiated at DA Davidson »

Renasant initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

FCCO

First Community

$18.31

(0.00%)

20:57
08/20/19
08/20
20:57
08/20/19
20:57
Initiation
First Community initiated at DA Davidson »

First Community initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

20:25
08/20/19
08/20
20:25
08/20/19
20:25
Conference/Events
Cantor Fitzgerald tech analyst to hold an analyst/industry conference call »

Technology & Business…

LOW

Lowe's

$98.04

3.07 (3.23%)

, TGT

Target

$85.57

-0.34 (-0.40%)

20:25
08/20/19
08/20
20:25
08/20/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

LOW

Lowe's

$98.04

3.07 (3.23%)

TGT

Target

$85.57

-0.34 (-0.40%)

ADI

Analog Devices

$110.35

-0.8 (-0.72%)

PLCE

Children's Place

$78.06

-2.6 (-3.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 21

    Aug

  • 21

    Aug

  • 21

    Aug

  • 15

    Sep

  • 19

    Sep

  • 25

    Sep

GOOG

Alphabet

$1,183.43

-14.58 (-1.22%)

, GOOGL

Alphabet Class A

$1,184.26

-15.68 (-1.31%)

19:02
08/20/19
08/20
19:02
08/20/19
19:02
Periodicals
YouTube intends to end targeted ads on videos aimed at children, Bloomberg says »

In an effort to satisfy…

GOOG

Alphabet

$1,183.43

-14.58 (-1.22%)

GOOGL

Alphabet Class A

$1,184.26

-15.68 (-1.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 27

    Oct

HMNY

Helios and Matheson

$0.00

(0.00%)

18:59
08/20/19
08/20
18:59
08/20/19
18:59
Periodicals
MoviePass exposed card data of thousands of customers, TechCrunch says »

MoviePass, which is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLM

PolyMet Mining

$0.34

-0.0125 (-3.60%)

18:49
08/20/19
08/20
18:49
08/20/19
18:49
Hot Stocks
PolyMet Mining reports court declined to hear petition for environmental review »

Poly Met Mining inc., a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAL

American Airlines

$25.83

-0.27 (-1.03%)

18:24
08/20/19
08/20
18:24
08/20/19
18:24
Hot Stocks
American Airlines to pay $22.1M to settle DOJ false claims act allegations »

The U.S. Justice…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

  • 05

    Sep

  • 23

    Sep

  • 14

    Nov

LZB

La-Z-Boy

$30.55

-1.325 (-4.16%)

, URBN

Urban Outfitters

$20.93

0.07 (0.34%)

18:17
08/20/19
08/20
18:17
08/20/19
18:17
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS:…

LZB

La-Z-Boy

$30.55

-1.325 (-4.16%)

URBN

Urban Outfitters

$20.93

0.07 (0.34%)

LEDS

SemiLEDs

$2.22

-0.05 (-2.20%)

NRZ

New Residential

$14.14

-0.115 (-0.81%)

NDSN

Nordson

$135.43

-1.79 (-1.30%)

CREE

Cree

$58.19

-0.09 (-0.15%)

SCSC

Scansource

$31.23

-0.56 (-1.76%)

JKHY

Jack Henry

$140.79

-0.72 (-0.51%)

TSLA

Tesla

$225.70

-1.05 (-0.46%)

WMT

Walmart

$112.12

-1.64 (-1.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 20

    Aug

  • 20

    Aug

  • 21

    Aug

  • 21

    Aug

  • 21

    Aug

  • 22

    Aug

  • 27

    Aug

  • 09

    Sep

  • 11

    Sep

  • 12

    Sep

  • 15

    Sep

  • 19

    Sep

  • 23

    Sep

  • 25

    Sep

  • 13

    Nov

  • 14

    Nov

LEDS

SemiLEDs

$2.22

-0.05 (-2.20%)

18:06
08/20/19
08/20
18:06
08/20/19
18:06
Hot Stocks
SemiLEDs receives offer from Chinese investor to acquire 680K shares »

On August 17, 2019,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$111.76

-0.72 (-0.64%)

18:01
08/20/19
08/20
18:01
08/20/19
18:01
Hot Stocks
Celanese announces ethyl acetate price increase in Europe »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$112.12

-1.64 (-1.44%)

17:50
08/20/19
08/20
17:50
08/20/19
17:50
Hot Stocks
Walmart's Furner sells nearly 8,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Sep

  • 25

    Sep

  • 13

    Nov

  • 14

    Nov

SPY

SPDR S&P 500 ETF Trust

$290.03

-2.28 (-0.78%)

, SPX

S&P 500

$0.00

(0.00%)

17:49
08/20/19
08/20
17:49
08/20/19
17:49
Periodicals
Bond manager Gundlach says Fed 'has lost control,' Reuters reports »

According to often quoted…

SPY

SPDR S&P 500 ETF Trust

$290.03

-2.28 (-0.78%)

SPX

S&P 500

$0.00

(0.00%)

QQQ

Invesco QQQ Trust

$186.99

-1.3 (-0.69%)

DIA

Diamonds Fund ETF

$259.61

-1.71 (-0.65%)

SMH

Market Vectors Semiconductor

$113.43

-0.64 (-0.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

URBN

Urban Outfitters

$20.93

0.07 (0.34%)

17:45
08/20/19
08/20
17:45
08/20/19
17:45
Earnings
Urban Outfitters CEO says Q2 was 'difficult quarter' for the company »

Urban Outfitter CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

  • 22

    Aug

  • 25

    Sep

17:45
08/20/19
08/20
17:45
08/20/19
17:45
General news
Breaking General news story  »

Federal Reserve Board of…

BA

Boeing

$331.94

-1.82 (-0.55%)

17:41
08/20/19
08/20
17:41
08/20/19
17:41
Hot Stocks
Boeing awarded $154.89M Army contract modification to procure Apache helicopters »

Boeing was awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Sep

CGC

Canopy Growth

$27.21

0.48 (1.80%)

17:35
08/20/19
08/20
17:35
08/20/19
17:35
Hot Stocks
GTEC provides update on acquisition of Canopy Growth cultivation facility »

GTEC Holdings provided an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.